Swiss Medica Inc. ein MUSS
Seite 1 von 4 Neuester Beitrag: 07.11.10 08:44 | ||||
| Eröffnet am: | 26.08.05 13:58 | von: RLDJA | Anzahl Beiträge: | 85 |
| Neuester Beitrag: | 07.11.10 08:44 | von: larsuwe | Leser gesamt: | 18.150 |
| Forum: | Hot-Stocks | Leser heute: | 4 | |
| Bewertet mit: |  | |||
| Seite: < | 2 | 3 | 4 > | ||||
Swiss Medica Inc. erforscht, entwickelt und vermarktet Medikamente auf pflanzlicher Basis. Ende 2004 gelang es dem unternehmen mit dem Schmerzlindernden Medikament "O24" einen Blockbuster rauszubringen. Der Umsatz konnte seit der Vermarktung innerhalb von einem Jahr verdoppelt werden. Neben dem drittgrößten Drug-Store in den USA "Rite Aid" kann man "O24" inzwischen in über 1.600 Geschäften erwerben. Teilweise mussten sich Händler das Produkt für Monate im Voraus sichern um einen Engpass in der Belieferung zu vermeiden. SwissMedica geht daher davon aus noch in diesem Jahr schwarze Zahlen zu schreiben.
According to David A. Bench, editor of The Research Works, Inc., Swiss Medica’s stock is “significantly undervalued... We are convinced that encouraging clinical trials and positive ‘word of mouth’ should translate into robust revenue growth within the next few quarters.
Die Aktie ist ein Muss für jeden Risikofreudigen Anleger.
SWISS MEDICA ANNOUNCES INSIDER BUYING PLAN
FOR IMMEDIATE RELEASE
Stock Symbol: OTC BB: SWME
Aug 25, 2005
SWISS MEDICA ANNOUNCES INSIDER BUYING PLAN
TORONTO-Swiss Medica, Inc. (OTCBB: SWME) is pleased to announce that Swiss Medica’s senior management team and members of Swiss Medica’s Board of Directors intend to purchase on the open market, shares of the Company's publicly traded Class A common stock, based on their assessment of prevailing market prices. Whether any such purchases are made, and the number of shares purchased, will depend upon the availability of shares at acceptable market prices. All trades will comply with Swiss Medica’s insider trading policy and insiders will file Form 4s with the S.E.C. as purchases are completed.
Mr. Raghu Kilambi, Swiss Medica’s CEO commented, “At current levels, we believe our stock is undervalued. These planned open market purchases illustrate our confidence in Swiss Medica’s underlying business strategy.”
TORONTO--(BUSINESS WIRE)--Aug. 29, 2005--Swiss Medica, Inc. (OTCBB:SWME) today announced that just weeks after hitting U.S. retail shelves, its recently-launched PMS Escape product has been selling out in many stores.
"We are pleased to see such strong initial sales for PMS Escape," notes Wendy Kramer, Swiss Medica's Vice President. "PMS Escape went into 5,000+ retail stores in late July and, in just two weeks, there have been reorders totaling more than 25% of the initial order. PMS is one of the most common women's health problems in the U.S. and with PMS Escape, women now have a safe and clinically proven way to help them manage the mood and appetite symptoms associated with premenstrual syndrome," adds Kramer.
PMS Escape is a clinically tested, patented, all natural product to help women with premenstrual syndrome (PMS) related disturbances in mood and appetite. It is the first over the counter product available at retail to help women manage these disturbances. PMS Escape is a powdered drink mix that contains the precise amounts of carbohydrates, vitamins and minerals that work naturally with the body to raise serotonin levels, which scientists believe decrease during PMS. For retail availability, customers can go to www.pmsescape.com.
About Swiss Medica Inc.
Swiss Medica commercializes proprietary bioscience products that relieve chronic ailments. We increase our market share through focused distribution strategies in multiple sales channels. Swiss Medica's mission is to be a world leader in the commercialization of life enhancing bioscience products that improve quality of lives. Please visit our websites at www.swissmedica.com ,www.O24zone.com and www.pmsescape.com
Swiss Medica's flagship product, the O24(TM) Essential Oil Pain Neutralizer, holds US Patent #6,444,238B1. The O24(TM) pain relief solution has been used, recommended and praised for its fast-acting and long-lasting benefits by healthcare professionals and athletes in the United States, Canada and in Europe. O24 is widely available throughout the United States and Canada in leading pharmacies and other retailers. Customers can also visit www.O24zone.com, for ordering details and store locators for the nearest pharmacy.
Swiss Medica is launching the patented O24(TM) Fibromyalgia pain reliever (US Patent #6,444,238B1) over-the-counter in North American retailers in the fall of 2005. The National Fibromyalgia Association (NFA) recently awarded O24(TM) Fibromyalgia their first NFA Seal of Approval. Upwards of 11 million Americans suffer from the long-term pain associated with fibromyalgia. In a randomized double blind clinical trial, more than 90 per cent of the patients who used O24 Fibromyalgia(TM) reported mild to markedly better improvement, versus only 7 per cent who used the placebo. Customers can visit www.024zone.com for information on O24 Fibromyalgia(TM) and to order the product online.
Swiss Medica also manufactures PMS Escape(R) which holds US Patent #'s 5760014 and 5612320. PMS Escape(R) is a specially formulated group of carbohydrates, vitamins and minerals, clinically proven to reduce changes in mood and appetite that women experience during the premenstrual period. Customers can also visit: www.pmsescape.com for additional information and ordering details.
Forward-looking statements in this news release are made pursuant to the "Safe Harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including, without limitation, risks relating to the ability to close transactions being contemplated, risks related to international sales and potential foreign currency exchange fluctuations, continued acceptance of Swiss Medica's products, increased levels of competition, technological changes, dependence on intellectual property rights and other risks detailed from time to time in Swiss Medica's periodic reports filed with the United States Securities and Exchange Commission and other regulatory authorities.
Quelle: DEL LA RUE - Investment Team
www.dellarue.de
www.SwissMedica.com
Tuesday September 20, 6:00 am ET
TORONTO--(BUSINESS WIRE)--Sept. 20, 2005--Swiss Medica, Inc. (OTC BB:SWME - News) is pleased to announce that Walgreens is now offering its O24 Pain Neutralizer product nationwide.
ADVERTISEMENT
"We are pleased that Walgreens has become the newest national pharmacy chain to carry O24 Pain Neutralizer," said Thomas Quinn, Swiss Medica's Executive Vice President. "We believe this will enable millions of people who suffer daily pain to have access to our patented, effective and safe pain reliever."
Die positiven Aussichten, noch diese Jahr schwarze Zahlen zu schreiben werden duch den regen Newsfloat bestärkt! Das erst vor gut zwei Jahren gegründete Unternehmen fuhr im ersten Geschäftshalbjahr rund 2,5 Mio USD Erlös ein. Die Prognosen wurden daher nach ablauf des ersten Halbjahres erhöht. Man geht von einem Jahresumsatz zwischen 12 - 14 Mio. USD aus. (im 3Q. 3-4 Mio. / im 4Q. 5-6 Mio / abhänging von Vertragsabschlüssen mit Einzelhandelsketten)
Die entspricht derzeit fast der Marktkapitalisierung von 18. Mio. USD.
O24 und PMS Escape werden inzwischen im immer mehr Drugstores verkauft und bestärken laut dem DEL LA RUE - Investment Team somit die Unternehmensprognosen!
Den vollen Bericht könnt ihr im Forum von www.dellarue.de nachlesen!
01.10.2005
Den jüngsten Abwärtstrend von Swiss Medica. Inc, beurteilen die Experten vom "DEL LA RUE - Investment Team" als günstige Nachkaufgelegenheit.
Man gehe davon aus, dass die Zahlen für das 3. Quartal bald veröffentlicht werden und im Rahmen der Prognosen liegen. Eine starke Kursexplosion halten wir für noch zu früh. Sollten die Prognosen auch im 4. Quartal bestätigt werden, wird mit einer Kusralley gerechnet. Die Kursziele liegen dabei zwischen 0.49 und 0.65 USD.
Wir raten investierten Anlegern bei Kursen bis zu 0.27 USD Nachzukaufen.
Erste Positionen sollten bis 0.35 USD aufgebaut werden.
Ein Update wird nach der Veröffentlichung der Zahlen für das 3.Q. folgen.
Swiss Medica to Present to Institutional Investors in Europe
Tuesday October 4, 6:00 am ET
TORONTO--(BUSINESS WIRE)--Oct. 4, 2005--Swiss Medica, Inc. (OTCBB:SWME - News) today announced that Chief Executive Officer, Raghu Kilambi will be making presentations to institutional investors on Swiss Medica and speaking at biotech investment conferences between October 4 and October 12th in Zurich, Cadaques (Spain), Paris, Brussels and London.
ADVERTISEMENT
Mr. Kilambi will present Swiss Medica on October 4-5th at the 5th Annual Biotech in Europe Investor Forum in Zurich, co-sponsored by Sachs Associates and Bloomberg LLP. In addition, Mr. Kilambi will present Swiss Medica on October 7-8th, 2005 at the invitation only Theime Small Cap Conference in Spain. The Thieme small cap conference showcases 6 carefully selected companies the Nanotechnology, Biotech and Energy fields.
Investors and analysts can view Swiss Medica's latest corporate and investor brochure at www.swissmedica.com.
Quelle: www.dellarue.de
Spannend könnte es in dieser Woche noch bei SWISS MEDICA werden, die sich auf Europa-Tour befinden und sich dort institutionellen Investoren präsentieren. Die Gesellschaft wird auf verschiedenen Konferenzen in Zürich, Cadaques, Paris, Brüssel und London vertreten sein und sein Geschäftsmodell vorstellen. Erste Station wird das 5. Jährliche Biotech in Europa Investor Forum in Zürich sein, das gestern begonnen hat und heute zu Ende geht. Kommenden Freitag und Samstag gastiert SWISS MEDICA im spanischen Cadaques bei der Thieme Small Cap Conference, auf der sich insgesamt 6 Unternehmen aus den Bereichen Nanotechnologie, Biotechnologie und Energie vorstellen. Gut möglich, dass sich im Anschluss an die Präsentationen auch im Kurs endlich wieder etwas tut, gestern ging es bereits 7 ½% auf USD 0.21 nach oben!
Wednesday October 19, 8:00 am ET
TORONTO--(BUSINESS WIRE)--Oct. 19, 2005--Swiss Medica, Inc. (OTCBB:SWME - News) third quarter revenues for the three months ended September 30, 2005, revenues grew to a record US$1.77 million - an increase of more than 28 percent over the Company's second quarter revenues of US$1.38 million. Nine month 2005 revenues exceeded US$4.28 million, a 583%-percent increase over full year 2004 revenues.
ADVERTISEMENT
"While we are pleased with the 28 percent quarter over quarter revenue growth, we are disappointed that our revenues were lower than previous guidance" said Chief Executive Officer, Raghu Kilambi. "Several US orders for O24 Fibromyalgia did not materialize prior to September 30th as previously expected, and Canadian regulatory delays did not allow Swiss Medica to launch PMS Escape and O24 Fibromyalgia in Canada in the third quarter. The good news is that in October to date, we have started to receive more US orders for O24 Fibromyalgia, and we now are able to sell O24 Fibromyalgia and PMS Escape in Canada."
Highlights in the Third Quarter included:
- Continued increased distribution for Swiss Medica's flagship O24 Pain Neutralizer. O24 Pain Neutralizer is now available in over 19,000 retail outlets in North America, including the top three drugstore chains in the United States and all major retailers in Canada.
- Swiss Medica launched PMS Escape in the United States and has distribution in over 5,000 pharmacy outlets. PMS Escape is the first patented, over-the-counter and clinically proven product to deal with the mood and appetite symptoms related to pre-menstrual syndrome. PMS Escape will be launched in Canada in the fourth quarter and will continue to get increased USA distribution.
- O24 Fibromyalgia continues to gain pre-retail excitement as the first clinically tested product specifically for Fibromyalgia. The National Fibromyalgia Association, based in California, has given O24 Fibromyalgia its first and only Seal of Approval. O24 Fibromyalgia will be available nationally in the United States and Canada during the fourth quarter of 2005.
"We continue to be optimistic about Swiss Medica's growth prospects given our three patented, clinically tested chronic ailment products will be available nationally in the United States and Canada during this fourth quarter ending December 31, 2005", said Mr. Kilambi. "However, due to delays in launching new products noted above and to be conservative, we are lowering our revenue guidance for 2005 and the fourth quarter ending December 31, 2005. For the three months ending December 31, 2005, Swiss Medica expects net revenues in excess of US$2 million. That would translate to fiscal 2005 revenues in excess of US$6.3 million. Despite the lower 2005 revenues, our strong gross margins should allow Swiss Medica to report positive EBITDA for the fourth quarter ending December 31st."
Swiss Medica defines EBITDA as earnings before interest and financing fees, taxes, depreciation, amortization, and other non-cash charges. Full second quarter results, for the period ending 30 September 2005, will be included in the Company's 10-Q, which will be filed with the U.S. Securities and Exchange Commission by November 15th.
About Swiss Medica, Inc.
Swiss Medica commercializes proprietary bioscience products that relieve chronic ailments. We increase our market share through focused distribution strategies in multiple sales channels. Swiss Medica's mission is to be a world leader in the commercialization of life enhancing bioscience products that improve quality of lives. Please visit our websites at www.swissmedica.com ,www.O24zone.com and www.pmsescape.com.
Swiss Medica's flagship product, the O24 Essential Oil Pain Neutralizer, holds US Patent #6,444,238B1. The O24 pain relief solution has been used, recommended and praised for its fast-acting and long-lasting benefits by healthcare professionals and athletes in the United States, Canada and in Europe. O24 is widely available throughout the United States and Canada in leading pharmacies and other retailers. Customers can also visit www.O24zone.com, for ordering details and store locators for the nearest pharmacy.
Swiss Medica is launching the patented O24 Fibromyalgia pain reliever (US Patent #6,444,238B1) over-the-counter in North American retailers in the fall of 2005. The National Fibromyalgia Association (NFA) recently awarded O24 Fibromyalgia their first NFA Seal of Approval. Upwards of 11 million Americans suffer from the long-term pain associated with fibromyalgia. In a randomized double blind clinical trial, more than 90 per cent of the patients who used O24 Fibromyalgia reported mild to markedly better improvement, versus only 7 per cent who used the placebo. Customers can visit www.024zone.com for information on O24 Fibromyalgia and to order the product online.
Swiss Medica also manufactures PMS Escape® which holds US Patent #'s 5760014 and 5612320. PMS Escape® is a specially formulated group of carbohydrates, vitamins and minerals, clinically proven to reduce changes in mood and appetite that women experience during the premenstrual period. Customers can also visit: www.pmsescape.com for additional information and ordering details.
Forward-looking statements in this news release are made pursuant to the "Safe Harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including, without limitation, risks relating to the ability to close transactions being contemplated, risks related to international sales and purchases and potential foreign currency exchange fluctuations, continued acceptance of Swiss Medica's products, increased levels of competition, technological changes, dependence on intellectual property rights and other risks detailed from time to time in Swiss Medica's periodic reports filed with the United States Securities and Exchange Commission and other regulatory authorities.
Swiss Medica, Inc. (OTC Bulletin Board:SWME - News)
22.10.2005
Swiss Medica Inc. veröffentlichte am 19. Oktober die Geschäftszahlen zum 3. Quartal 2005.
Mit einem Umsatzwachstum von 28% auf 1.77 Mil. USD gegenüber 1.38 Millionen USD im 2. Quartal 2005, lag der Umsatz deutlich unter den Erwartungen von ca. 3 Millionen USD.
Anders als erwartet, konnte der Verkauf von PMS Escape und O24 Fibromyalgia in Kanada erst im Oktober und nicht wie geplant im August beginnen. Hinzu konnten zahlreiche amerikanische O24 Fibromyalgia Aufträge nicht vor dem 30. September verwirklicht werden.
Raghue Kilambi, CEO, teile jedoch ebenfalls mit, dass der Verkauf in Kanada und Amerika bereits im Oktober begonnen hat. Mittlerweile wird O24 Fibromyalgia in über 5.000 Geschäften angeboten. Bis zum Jahresende soll sich die Anzahl der Geschäfte auf 10.000 verdoppelt haben. Der CEO erwartet für das 4. Quartal einen Umsatz von 2 Millionen USD und hofft auf ein positives EBITDA.
Die Experten vom " DEL LA RUE – Investment Team“ halten Swiss Medica Inc. weiterhin für überdurchschnittlich lukrativ. Man geht davon aus, dass sich der Umsatz in 2006 weiter positive entwickelt und ein Jahresumsatz zwischen 12 und 15 Millionen realistisch erscheint. Angesichtes dessen ist die Swiss Medica Inc. bei einem Kurs von momentan 0.14 USD deutlich unterbewertet und nach Meinungen des Investment –Teams ein Muss für ihre Anleger.
TORONTO--(BUSINESS WIRE)--Nov. 28, 2005--Swiss Medica, Inc. (OTCBB:SWME) today announced that it has been awarded the Arthritis Foundation's (Northern California Chapter) prestigious 2005 Corporate Award. Grant Johnson, President and COO of Swiss Medica, along with Richard Weise, the inventor of O24, will be in attendance to accept the award on December 7, 2005, at the Annual Meeting of the Northern California Chapter of the Arthritis Foundation in San Francisco.
The award singles out Swiss Medica from a field of potential corporate candidates for the honor. Swiss Medica received this designation because it was determined that the Company has done more to assist the Foundation in its mission to advance its causes than any other contender.
In September 2005, Swiss Medica was Presenting Sponsor for the Arthritis Foundation's (Northern California Chapter) inaugural Arthritis Expo held in Santa Clara. Swiss Medica provided sponsorship funding, substantial product sampling, and on site participation by medical professionals.
The event provided an excellent opportunity to sample Swiss Medica's flagship product O24 Pain Neutralizer to a large segment of the Foundation's membership and physicians. Due in large part to the positive reaction to O24 Pain Neutralizer, product samples will be included in Northern California Chapter Arthritis Foundation member mailing being distributed in early 2006. O24 Pain Neutralizer is a medically and clinically tested product that has made a significant difference in the lives of many people living with the day to day challenges of pain associated with arthritis.
James R. Bouquin, President of the Northern California Chapter of the Arthritis Foundation says "Swiss Medica exemplifies the kind of corporate citizen that makes a real difference to the work of our organization and our members who are living with arthritis."
The Northern California Chapter of the Arthritis Foundation represents 2 million people in the Greater San Francisco Bay area managing Arthritis.
DEL LA RUE Börsenbrief: Ausgabe I-05,
2. Dezember 2005
O24 in über 21,000 Geschäften
Seit der Einführung von SwissMedica‘s O24 Pain Relief sind nicht einmal drei Jahre vergangen und das Unternehmen konnte schon jetzt bekannt geben, das O24 in über 21,000 Geschäften in den USA und Kanada käuflich zu erwerben ist. Abnehmer von O24 sind vor allem große Drugstores, wie CVS, Rite Aid, Longs Drugs, Walgreens aber auch Wal-Mart (Kanada).
Auch das neuste Produkt O24 Fibromyalgia, soll bis Jahresende in über 10,000 Geschäften zu kaufen sein.
Die Geschichte von SwissMedica, halten wir nach wie vor für äußerst interessant und lukrativ. Wir können daher unseren Lesern nur empfehlen, in diesen Wert investiert zu sein.
Auf der Homepage www.swissmedica.de, bietet das Unternemen erste Informationen über eine Anlage:
Zinssatz: 12 %
Laufzeit: 5 Jahre
min. Anlagebetrag: 200.000 EURO
Informationen über das Unternehmen und Produkte sollen anfang 2006 erscheinen.
in den USA eine 12% Verzinsung
in der EU eine 9,5% Verzinsung
Swiss Medica Confirms Record Net Revenues in Excess of US$2 Million in Fourth Quarter
Thursday December 22, 8:00 am ET
TORONTO--(BUSINESS WIRE)--Dec. 22, 2005--Swiss Medica, Inc. (OTCBB:SWME - News) is pleased to announce that net revenues for the fourth quarter ending December 31, 2005 will be in excess of US$2 million. This revenue level is in line with the updated guidance that was given in the press release dated October 19, 2005. Fiscal 2005 revenues will be in excess of US$6.3 million.
Swiss Medica will announce final fourth quarter net revenues and other fourth quarter operating highlights by January 13th, 2006. Full fourth quarter and fiscal 2005 audited financial statements will be included in the Company's 10-K, which will be filed with the U.S. Securities and Exchange Commission by March 31, 2006.
Swiss Medica CEO Raghu Kilambi commented, "We are pleased with our continued growth in the fourth quarter and growing acceptance for our three products in North America. We are confident that 2006 will bring further growth and expansion into new channels and markets."
15.07.2003
"SWME recently announced it's first investment in Doctor's Natural Solutions Inc. in a deal that will ultimately result in Swiss Medica acquiring a biosciences product called Ayala, a significant discovery in the field of "Blood Sugar Management." Doctor's Natural Solutions, based in Clearwater, Florida, developed Ayala, a herbal product suite with potential practical applications ranging from significant weight loss and weight management to diabetes therapy. After two years of development and a number of successful case studies, Ayala is expected to be ready for commercialization in 2003."
Nach längeren Recherchen haben wir erfahren, dass der Deal aus nicht bekannten Gründen platzte und das Produkt sowie das Unternehmen "Doctor's Natural Solutions", nicht länger bestehen.
Quelle: www.dellarue.de
Fast zwei Monate nach bekanntwerden der Swiss Medica Deutschland GmbH,
wurde der Internetauftritt zu heute wesentlich verbessert.
Die Swiss Medica Deutschland GmbH bietet interessierten Anlegern ausfühliche Informationen über den Erwerb von Genussscheinen.
Der Genussschein bedarf einem Mindestinvestment von derzeit noch 200.000 EURO.
Die verzinsung beträgt 9,5% pro Jahr. Nach zwei Jahren fester Laufzeit besteht die Möglichkeit das Investment jährlich zu verlängern oder zu kündigen.
Produkte und Unternehmensinformationen sollen schon in Kürze folgen.
Ihr
DEL LA RUE
Investment Team
TORONTO--(BUSINESS WIRE)--Jan. 17, 2006--Swiss Medica, Inc. (OTCBB:SWME) is pleased to announce fourth quarter net revenues, fiscal year 2005 revenues and operating highlights.
- Net revenues for the fourth quarter ending December 31, 2005 were US$2.136 million - an increase of 21% over third quarter 2005 revenues. This represents the 5th consecutive quarter of revenue growth.
- Net revenues for 2005 grew to US$6.42 million - an increase of 924% over fiscal year 2004.
- O24 Pain Neutralizer is now available in over 21,000 retail outlets in both the USA and Canada, including Walgreens, CVS Pharmacy, Rite Aid, Shoppers' Drug Mart, Wal-Mart Canada and Loblaws.
- Swiss Medica also launched O24 Fibromyalgia and PMS Escape into national retailers in the USA.
Other achievements include:
1. Swiss Medica and O24 Pain Neutralizer received the "Company of the Year" and "Product of the Year" awards from the Northern California Arthritis Foundation.
2. O24 Fibromyalgia became the first clinically tested product specifically for Fibromyalgia to be available in drug stores in the USA, including Rite Aid, Sav-On Drugs and Longs Drugs. O24 Fibromyalgia has received the first and only Seal of Approval from the National Fibromyalgia Association in California. O24 Fibromyalgia will be available in over 15,000 retail outlets in USA by the end of the first quarter of 2006.
3. O24 Fibromyalgia underwent a double blind clinical study at a hospital affiliated with the University of Toronto with outstanding results. Over 90% of participants who used O24 had a reduction in pain versus only 7% who used the placebo.
4. PMS Escape, the only clinically proven OTC product to help ease mood and appetite symptoms of pre-menstrual syndrome is now available at CVS Pharmacy. PMS Escape was developed by renowned MIT (Massachusetts Institute of Technology) academics, and completed successful double blind studies at MIT, Harvard and University of Pennsylvania with excellent results.
5. O24 samples and product information are being distributed by thousands of physicians and other medical professionals to their patients in Canada and USA.
Swiss Medica's management will host a conference call on Wednesday January 25th, 2006 at 4:00 pm EST to discuss the Company's fourth quarter highlights and go forward strategy. Callers from the Toronto area are invited to dial 416-695-9753 at that time to participate. All other callers are invited to dial 1-877-888-4605 to participate. The conference will also be webcast with a direct link from www.swissmedica.com.
Swiss Medica CEO, Raghu Kilambi commented "We are pleased with Swiss Medica's growth in 2005 and are confident that 2006 will be a watershed year for the company and its products as we capitalize on the branding achievements of 2005, and expand distribution of our products into new geographical markets and other channels."
Full fourth quarter and fiscal 2005 audited financial statements will be included in the Company's 10-K, which will be filed with the U.S. Securities and Exchange Commission by March 31, 2006.
TORONTO--(BUSINESS WIRE)--Jan. 18, 2006--Swiss Medica, Inc. (OTCBB:SWME) is pleased to announce that according to sales rankings for the latest 52-week period ending November 30, 2005 by ACNielsen, the 30ml spray bottle of O24 Pain Neutralizer was ranked the fourth best selling product in the topical analgesic pain relief category in Canadian drug stores, based on dollar sales at the retail level. O24 Pain Neutralizer was nationally launched in Canadian drug stores in September 2004.
Swiss Medica's Vice President Canadian Sales, Anne Dundon commented "O24 Pain Neutralizer has continued to prove itself in the retail marketplace in Canada. The product is gaining strong acceptance from consumers suffering from muscle aches and pains - plain and simple, this patented all-natural product works."
Swiss Medica's President and COO, Grant Johnson noted "We are extremely pleased with the quick acceptance this product has gained in Canada from consumers, retailers and the medical community within 15 months of national distribution. Our Canadian business recorded just under C$2.0 million in net revenues for 2005 (approximately US$1.7 million) and we expect continued high growth in 2006 as we launch O24 Fibromyalgia and PMS Escape into the Canadian marketplace. In addition, the success of O24 Pain Neutralizer is an excellent indicator of the potential for O24 in the United States as Canada's population is approximately 10 percent the size of that of the United States."
17.01.2006
Das Investment Team von “DEL LA RUE“ ist sich nach den guten Zahlen vom 4. Quartal einig, Swiss Medica wird ein Highflyer in 2006.
Spektakuläre Kurssprünge sind nach der Erstempfehlung im August 2005 ausgeblieben. Stattdessen verlor die Aktie bis zu 60% an Wert.
Steigt der Umsatz wie zuletzt pro Quartal um gut 20%, dürfte Swiss Medica 2006 Umsätze von über 10 Mio. USD einfahren. Das entspricht fast der derzeitigen Marktkapitalisierung. Für ein Unternehmen das seine Geschäftstätigkeiten erst 2003 aufgenommen hat und sich auf Expansionskurs befindet, wäre eine drei bis fünffache Marktkapitalisierung angemessen.
Zudem könne man bei Swiss Medica auch in naher Zukunft mit weiteren Produkteinführungen rechnen, was bei den Anlegern für große Spekulationen sorgen wird. Wir erinnern daran, das Swiss Medica 2003 neun deutsche Patente von General Cosmetics Corp. Erwarb, wobei bereits drei Marktfähig waren.
Ende 2005 wurde in Deutschland das Tochterunternehmen „Swiss Medica GmbH Deutschland“ gegründet, eine Bekanntgabe liegt noch immer nicht vor. Auf der Homepage wird aber bereits für eine Anlage geworben. Am 25. Januar wird eine Konferenz gehalten, wo Raghu Kilambi über weitere geschäftliche Maßnahmen, sowie über die Expansion in neue geographische Gebiete informieren wird. Für uns ein Hinweis, dass über die EU-Expansion, sowie die Ausgabe der Genusscheine informiert werden soll.
Für uns ist Swiss Medica Inc. ein klassisches aufsteigendes Pioneerunternehmen.
Wir stufen die Aktie mit Strong-Buy ein und erhöhen unser Kursziel.
Unser 12-Monats-Ziel beträgt 0,60 USD (Marktkap. 58 Mio. USD)
Unser 24-Monats-Ziel beträgt 1,04 USD (Marktkap. 100 Mio. USD)
Ebenfalls wird die Homepage momentan fast täglich aktualisiert, sprich, es sind nun auch erste Erfahrungsberichte und Kontaktadressen, sowie Bilder von den Produkten Online.
Swiss Medica, Inc. (OTCBB:SWME) today announced the Canadian launch of Swiss Medica's patented O24 Fibromyalgia across Canada at Shoppers Drug Mart and other retailers. O24 Fibromyalgia is the first patented product specifically targeting patients to fight the intense, debilitating pain caused by Fibromyalgia. O24 Fibromyalgia is also available across the United States in leading drug store chains including Rite Aid, Save-On Drugs and Longs Drugs.
Anzeige:
Langfristiger Vermögensaufbau - Staatliche Förderung schafft bis zu 75% Abschreibung! Jetzt informieren!
The launch of O24 Fibromyalgia, in its distinctive blue box with orange lettering, follows the successful Canadian launch of Swiss Medica's flagship product, O24 Pain Neutralizer nationally in Canada. AC Nielson ratings recently ranked O24 Pain Neutralizer's 1 ounce bottle as the 4th best selling topical pain reliever in Canada.
Swiss Medica has entered into a strategic partnership with FM-CFS Canada, the group representing Fibromyalgia patients in Canada. Executive Director John Ernst says "Swiss Medica has demonstrated commendable dedication to Fibromyalgia patients by conducting clinical research on products that help those who live with the condition. We have heard good reports from those we've asked to try the O24 Fibromyalgia product."
Fibromyalgia is a chronic syndrome characterized by widespread musculoskeletal pain, fatigue, and multiple tender points that occur primarily in the neck, spine, shoulders, and hips. Fibromyalgia is known to cause sleep disturbances, morning stiffness, irritable bowel syndrome, anxiety and other symptoms, and afflicts over 1 million Canadians.
In early 2005, Swiss Medica conducted research which involved a double blind clinical trial by Dr. Gordon Ko (Head, Fibromyalgia Clinic) and Dr. David Berbrayer (Head, Dept. Rehabilitation Medicine) at Sunnybrook & Women's Health Sciences Centre (University of Toronto). This clinical trial, conducted over a four to six week period, compared O24 Fibromyalgia against a placebo in patients suffering with Fibromyalgia. For participants who used O24 Fibromyalgia, more than 90 per cent of the patients reported mild to markedly better improvement on the 7-point Lanier rating scale, versus 7 per cent who used the placebo. Nearly 54% reported moderately better or markedly better results using O24 Fibromyalgia instead of the placebo.
Swiss Medica's President and Chief Operating Officer, Grant Johnson stated "The launch of O24 Fibromyalgia in Canada represents a number of firsts. This is the first patented product specifically for people with Fibromyalgia. We are the first to enter into a strategic and mutually beneficial agreement with Canada's national voice for the Fibromyalgia community, the FM-CFS (Fibromyalgia and Chronic Fatigue Syndrome) of Canada. Last and certainly not least, O24 Fibromyalgia is the first specific Fibromyalgia product to be available nationwide over-the-counter in Canada's largest drug store chain."
As a reminder, please note that Swiss Medica will be hosting a shareholder conference call on Wednesday, January 25, 2006 at 4:00pm EST. Toronto area callers are asked to dial 416 695 9753. All other callers, please dial 1 877 888 4605.
The conference call will also be webcast with a direct link on www.swissmedica.com.